New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 4, 2012
12:41 EDTQGENQIAGEN reaffirms FY12 EPS view $1.04-1.06, consensus $1.00
Sees revenue up approximately 8-9% CER on a mix of contributions from the acquisitions of Cellestis and Ipsogen in 2011 and AmniSure in May 2012, as well as growth in the rest of the business. Full-year reported sales are expected to be adversely affected by currency movements against the U.S. dollar, QIAGEN's reporting currency.This guidance takes into account approximately half a cent of dilution expected on adjusted EPS results in the fourth quarter of 2012 from the combined effect of the share repurchase program as well as higher interest expenses incurred through the U.S. private placement. These expectations do not take into account any further acquisitions that could be completed in 2012.
News For QGEN From The Last 14 Days
Check below for free stories on QGEN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 10, 2014
16:02 EDTQGENQIAGEN acquires exclusive worldwide license to biomarker calreticulin
Subscribe for More Information
April 2, 2014
09:01 EDTQGENLeerink's life science tools analyst holds an analyst/industry conference call
Life Science Tools Analyst Leonard discusses the use of nextgen sequencing in a clinical context, early applications and uptake, the merits, demerits of various nextgen sequencing instruments and where new offerings fit on an Analyst/Industry conference call. Relevant companies ILMN, TMO, PACB, FLDM, MYGN, NSTG, GNMK, CPHD, LMNX and QGEN may be discussed on the Analyst/Industry conference call to be held on April 3 at 2 pm.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use